Anthony W. Tolcher

A. Tolcher 400X400.jpg

Anthony W. Tolcher, M.D., FRCPS(C), FACP, is CEO and Founder of NEXT OncologyTM, San Antonio, Texas, a Phase I group that seeks to transform early clinical trials. Previously Dr. Tolcher served as President and Co‐Founder of START LLC from 2008‐2018, locations in San Antonio Texas; Grand Rapids, Michigan; Madrid Spain; and Shanghai China. 

Dr. Tolcher is a medical oncologist who has over 25 years’ experience in early drug development and clinical trials. He has been involved in more than 21 of the initial Phase 1 studies of new agents that subsequently were FDA approved for the treatment of cancer including pembrolizumab (Keytruda®), durvalumab (Imfinzi®), trastuzumab emtansine (Kadcyla®) and regorafenib (Stivarga®). 

He is currently the principal investigator of over 20 Phase 1 clinical studies, is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research, and Annals of Oncology. He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program. Dr. Tolcher has over 130 peer‐reviewed publications in scientific journals including Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology, and Clinical Cancer Research, as well as an author of nine book chapters.

A. Tolcher 400X400.jpg